colorectal cancer. malignant neoplasm of colon
Conditions
Interventions
Intervention 1: Intervention group: patient who take duloxetine 30mg/d for first week and then 30 mg BD to 12 weeks. Intervention 2: Control group: Patients in this group receive one placebo capsule d
Sponsors
Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Over 18 years old The candidate patient is going to get his/her first chemotherapy course with Oxaliplatin drug
Exclusion criteria
Exclusion criteria: The patient has no uncontrolled diabetes mellitus or uncontrolled hypertension The patient is not taking drugs which have interaction with Duloxetin The patient is not on liver metastatic stage History of duloxetine allergy hepatic impairment clcr < 30ml/min and ESRD
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Peripheral neuropathy. Timepoint: every 2-3 week. Method of measurement: FACT/GOG-NTX-13 and NCI-CTCAE questionaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| Quality of life. Timepoint: at baseline and 12 weeks later. Method of measurement: FACT-C version 4 questionaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactRokhsareh Soufi
Shahid Beheshti University of Medical Sciences
Outcome results
None listed